TY - JOUR T1 - Pre-emptive deceased-donor kidney transplant: A matched cohort study JO - Nefrología (English Edition) T2 - AU - Franco,Antonio AU - Más-Serrano,Patricio AU - González,Yussel AU - Balibrea,Noelia AU - Rodríguez,David AU - López,María Isabel AU - Contreras,Francisco Javier Pérez SN - 20132514 M3 - 10.1016/j.nefroe.2019.04.006 DO - 10.1016/j.nefroe.2019.04.006 UR - https://www.revistanefrologia.com/en-pre-emptive-deceased-donor-kidney-transplant-a-articulo-S2013251420300122 AB - IntroductionCurrently, kidney transplantation is the treatment of choice for patients with kidney disease who require replacement therapy. Dialysis is a necessary step, but not mandatory prior to transplantation. There is the possibility of pre-emptive transplantation or transplantation in pre-dialysis, that is, without previous dialysis. The aim of the present study is to evaluate the result of our experience with a pre-emptive kidney transplant from a deceased donor. Materials and methodsRetrospective, observational, matched cohort study. We compared 66 pre-emptive with 66 non pre-emptive recipients, who received a first renal graft performed at our centre, matched by age and gender of donors and recipients, time of transplant, immunological risk, immunosuppression and cold ischaemia time.Early graft loss, incidence of acute rejection, delayed graft function, renal function at 12 and 36 months and graft and recipient survival were assessed in this period. ResultsThe percentage of recipients who presented early graft loss, delayed graft function and acute rejection was similar in both groups. No differences were observed in their renal function at 12 and 36 months after transplantation, as well as the actuarial survival of patients (p = 0.801) and grafts (p = 0.693) in the studied period. The total calculated cost of the period on dialysis for the control group was 8,033,893.16 euros. ConclusionsPre-emptive transplantation can yield comparable outcomes to those for post-dialysis kidney transplantation, and results in better quality of life for patients with end-stage kidney disease, as well as a reduced cost. ER -